Yasumitsu T, Ohshima S, Nakano N, Kotake Y, Tominaga S
Department of Surgery, Osaka Prefectural Habikino Hospital, Japan.
Acta Oncol. 1990;29(6):827-31. doi: 10.3109/02841869009093009.
A randomized study with and without bestatin, a new biological response modifier, was conducted in order to evaluate its survival effect on resected lung cancer. A total of 153 patients (72 with squamous cell carcinoma, 66 with adenocarcinoma, and 15 with other types of cancer) were evaluated. Among the patients with squamous cell carcinoma, the bestatin-treated group had significantly prolonged survival compared to the control group. No significant difference between the two groups was seen in adenocarcinoma.
为了评估一种新型生物反应调节剂贝司他汀对切除的肺癌患者的生存影响，进行了一项有或没有贝司他汀的随机研究。总共评估了153例患者（72例鳞状细胞癌、66例腺癌和15例其他类型癌症）。在鳞状细胞癌患者中，与对照组相比，贝司他汀治疗组的生存期显著延长。腺癌患者两组之间未见显著差异。
